Longer Souvenaid trials
May 29, 2014
SOUVENAID creator Professor
Richard Wurtman said trials for the
medical food needed to be longer
to assess whether it had any effect
in delaying Alzheimer’s Disease
(AD).
Wurtman presented at the Sydney
General Practitioner Conference
& Exhibition last week, joined by
University of Newcastle School
of Medicine and Public Health
discipline of general practice and
Souvenaid advisory board member
Professor Dimity Pond, who gave
case studies of its use.
An NPS Medicinewise article in
January said there was no evidence
that Souvenaid had any effect in
decreasing the rate of cognitive
decline or delaying AD progression,
but said there might be an effect on
memory performance in drug-naive
persons in the early stages of the
disease.
Wurtman said the question
became how long would a
study have to be run to reliably
demonstrate cognitive decline in
untreated people.
The general view was a year and
a half, and this would not occur
before a six month study and one
year study, he said.
Currently, Souvenaid trials have
spanned 24 weeks.
It would be more accurate to say
there was no evidence yet, he said.
Longer trials were in the works,
he said.
The above article was sent to subscribers in Pharmacy Daily's issue from 29 May 14To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 29 May 14
